Compare Gartner Inc (IT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Revvity Inc — how do they compare? Gartner Inc trades at $195.41 (market cap $11.73B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Revvity Inc for 12 Days on average.
| IT | RVTY | |
|---|---|---|
Market Cap | $11.73B | $17.14B |
Volume | 736,899 | 2,226,396 |
Sector | Technology | Health |
52-Week High | $258.17 | $157.36 |
52-Week Low | $125.68 | $82.26 |
Typical Hold Time | 64 Days | 12 Days |
Enterprise Value | $13.48B | $19.46B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.77, up 0.46% today, showing strong technical momentum with a bullish moving average signal. The company maintains robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and impressive profitability metrics including 69.63% gross margin and 113.58% ROE. Recent news highlights Gartner's leadership position in AI advisory services and strong industry recognition.
While valuation appears reasonable with P/E of 16.71, the stock faces headwinds from negative cash flow trends and a high P/B ratio of 160.06. Analyst consensus is mixed with 27.78% buy ratings but a consensus price target below current levels at $174.63, suggesting limited near-term upside potential despite strong business fundamentals.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
